- Home
- MAX vs SGP Comparison
MAX vs SGP Comparison
Compare MAX & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAX | SGP |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | 65 |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.5M | 650.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | MAX | SGP |
|---|---|---|
| Price | $12.41 | $22.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $12.70 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 1.1M | 105.5K |
| Earning Date | 04-29-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.81 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $1,113,600,000.00 | N/A |
| Revenue This Year | $13.42 | N/A |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | $14.40 | ★ N/A |
| Revenue Growth | ★ 28.78 | N/A |
| 52 Week Low | $7.09 | $17.06 |
| 52 Week High | $14.70 | $30.56 |
Technical Indicators
Market Signals| Indicator | MAX | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 59.76 |
| Support Level | $11.09 | $20.95 |
| Resistance Level | $14.21 | $22.54 |
| Average True Range (ATR) | 0.72 | 1.35 |
| MACD | -0.25 | 0.24 |
| Stochastic Oscillator | 7.79 | 70.24 |
Price Performance
Historical ComparisonAbout MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.